MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus
Extensive lymphatic malformations (LM) may cause substantial morbidity. The mTOR (mammalian target of rapamycin) inhibitor sirolimus shows promise for treating vascular anomalies, though response assessment is not standardized. To retrospectively characterize changes on MRI in extensive LM in childr...
Gespeichert in:
Veröffentlicht in: | American journal of roentgenology (1976) 2021-09, Vol.217 (3), p.741-752 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 752 |
---|---|
container_issue | 3 |
container_start_page | 741 |
container_title | American journal of roentgenology (1976) |
container_volume | 217 |
creator | Durand, Rachelle Reid, Janet R Belasco, Jean B Shellikeri, Sphoorti Calle-Toro, Juan S Cahill, Anne Marie Srinivasan, Abhay |
description | Extensive lymphatic malformations (LM) may cause substantial morbidity. The mTOR (mammalian target of rapamycin) inhibitor sirolimus shows promise for treating vascular anomalies, though response assessment is not standardized.
To retrospectively characterize changes on MRI in extensive LM in children treated with sirolimus.
Twenty-five children treated with sirolimus for extensive LM were included. Baseline MRI was defined as MRI closest to therapy initiation; follow-up MRI was defined as most recent MRI while on therapy. Two pediatric radiologists independently determined MRI lesion volume by tracing lesion contours on all slices (normalized to patient body mass index) and signal by placing an ROI on lesions' dominant portion (normalized to CSF signal), on baseline and follow-up T2-weighted sequences. Inter-reader agreement was determined, and values averaged for further analysis. Volume and signal changes were compared with patient, lesion, and therapy characteristics.
Mean (±SD) interval between sirolimus initiation and follow-up MRI was 22.1±13.8 months. Mean lesion volume index on baseline and follow-up MRI was 728 mL/m2 ± 970 mL/m2 and 345 mL/m2±501 mL/m2, respectively (p10% (mean volume change -46.4%±28.2%). Volume change was inversely correlated with age (r=-0.466, p=.02). Mean volume change was -64.7%±25.4% in children under 2 years old versus -32.0%±21.6% in remaining children (p=.008). Mean volume change was -58.1%±24.0% for craniocervical lesions versus -35.5%±28.2% for body and extremity lesions (p=.03). Mean lesion signal ratio on baseline and follow-up MRI was 0.81±0.29, and 0.59±0.26, respectively (p.05). Inter-reader agreement for volume index change was excellent [intraclass correlation coefficient (ICC)=0.983] and for signal ratio change was moderate-good (ICC=0.764).
Sirolimus treatment for extensive LM in children is associated with significant reductions in volume and signal on T2-weighted MRI. The volume decrease is greater in younger children and craniocervical lesions.
The results may facilitate development of standardized MRI-based criteria for assessing pharmacotherapy response of |
doi_str_mv | 10.2214/AJR.20.24378 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2476127756</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2476127756</sourcerecordid><originalsourceid>FETCH-LOGICAL-c291t-d6a39dbe30fa22fc0860b5c334867853c6c6240578bd00152a5f70a0df0287ad3</originalsourceid><addsrcrecordid>eNo9kEtPAjEUhRujEUR3rk2XLhzsa9phSQgqBmKCGN1NOn2EmnnZzhj595aAru5ZfOfk5gPgGqMxIZjdT5_XYxIzoyI7AUOcMp5QzPApGCLKcZIh-jEAFyF8IoRENhHnYEApQ-mEsSFQq_UC2sbDtQltUwcDpyGYECpTd7CxcP7TmTq4bwOXu6rdys4puJJlbFQxxwJ0NZxtXam9qeHGG9kZDd9dt4Wvzjelq_pwCc6sLIO5Ot4ReHuYb2ZPyfLlcTGbLhNFJrhLNJd0ogtDkZWEWIUyjopUxV8zLrKUKq44iX-LrNAI4ZTI1AokkbaIZEJqOgK3h93WN1-9CV1euaBMWcraNH3ICRMcEyFSHtG7A6p8E4I3Nm-9q6Tf5Rjle6151JqTmPdaI35zXO6Lyuh_-M8j_QUktnK9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476127756</pqid></control><display><type>article</type><title>MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus</title><source>American Roentgen Ray Society</source><source>Alma/SFX Local Collection</source><creator>Durand, Rachelle ; Reid, Janet R ; Belasco, Jean B ; Shellikeri, Sphoorti ; Calle-Toro, Juan S ; Cahill, Anne Marie ; Srinivasan, Abhay</creator><creatorcontrib>Durand, Rachelle ; Reid, Janet R ; Belasco, Jean B ; Shellikeri, Sphoorti ; Calle-Toro, Juan S ; Cahill, Anne Marie ; Srinivasan, Abhay</creatorcontrib><description>Extensive lymphatic malformations (LM) may cause substantial morbidity. The mTOR (mammalian target of rapamycin) inhibitor sirolimus shows promise for treating vascular anomalies, though response assessment is not standardized.
To retrospectively characterize changes on MRI in extensive LM in children treated with sirolimus.
Twenty-five children treated with sirolimus for extensive LM were included. Baseline MRI was defined as MRI closest to therapy initiation; follow-up MRI was defined as most recent MRI while on therapy. Two pediatric radiologists independently determined MRI lesion volume by tracing lesion contours on all slices (normalized to patient body mass index) and signal by placing an ROI on lesions' dominant portion (normalized to CSF signal), on baseline and follow-up T2-weighted sequences. Inter-reader agreement was determined, and values averaged for further analysis. Volume and signal changes were compared with patient, lesion, and therapy characteristics.
Mean (±SD) interval between sirolimus initiation and follow-up MRI was 22.1±13.8 months. Mean lesion volume index on baseline and follow-up MRI was 728 mL/m2 ± 970 mL/m2 and 345 mL/m2±501 mL/m2, respectively (p<.001). Ninety-two percent demonstrated a decrease in volume index >10% (mean volume change -46.4%±28.2%). Volume change was inversely correlated with age (r=-0.466, p=.02). Mean volume change was -64.7%±25.4% in children under 2 years old versus -32.0%±21.6% in remaining children (p=.008). Mean volume change was -58.1%±24.0% for craniocervical lesions versus -35.5%±28.2% for body and extremity lesions (p=.03). Mean lesion signal ratio on baseline and follow-up MRI was 0.81±0.29, and 0.59±0.26, respectively (p<.001). Mean signal ratio change was -23.8%±22.7%. Volume and signal changes were moderately correlated (r=0.469; p=.02). Volume and signal changes were not associated with sex, lesion subtype, sirolimus serum concentration, or interval between sirolimus initiation and follow-up MRI (p>.05). Inter-reader agreement for volume index change was excellent [intraclass correlation coefficient (ICC)=0.983] and for signal ratio change was moderate-good (ICC=0.764).
Sirolimus treatment for extensive LM in children is associated with significant reductions in volume and signal on T2-weighted MRI. The volume decrease is greater in younger children and craniocervical lesions.
The results may facilitate development of standardized MRI-based criteria for assessing pharmacotherapy response of vascular malformations.</description><identifier>ISSN: 0361-803X</identifier><identifier>EISSN: 1546-3141</identifier><identifier>DOI: 10.2214/AJR.20.24378</identifier><identifier>PMID: 33405944</identifier><language>eng</language><publisher>United States</publisher><ispartof>American journal of roentgenology (1976), 2021-09, Vol.217 (3), p.741-752</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c291t-d6a39dbe30fa22fc0860b5c334867853c6c6240578bd00152a5f70a0df0287ad3</citedby><cites>FETCH-LOGICAL-c291t-d6a39dbe30fa22fc0860b5c334867853c6c6240578bd00152a5f70a0df0287ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4106,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33405944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Durand, Rachelle</creatorcontrib><creatorcontrib>Reid, Janet R</creatorcontrib><creatorcontrib>Belasco, Jean B</creatorcontrib><creatorcontrib>Shellikeri, Sphoorti</creatorcontrib><creatorcontrib>Calle-Toro, Juan S</creatorcontrib><creatorcontrib>Cahill, Anne Marie</creatorcontrib><creatorcontrib>Srinivasan, Abhay</creatorcontrib><title>MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus</title><title>American journal of roentgenology (1976)</title><addtitle>AJR Am J Roentgenol</addtitle><description>Extensive lymphatic malformations (LM) may cause substantial morbidity. The mTOR (mammalian target of rapamycin) inhibitor sirolimus shows promise for treating vascular anomalies, though response assessment is not standardized.
To retrospectively characterize changes on MRI in extensive LM in children treated with sirolimus.
Twenty-five children treated with sirolimus for extensive LM were included. Baseline MRI was defined as MRI closest to therapy initiation; follow-up MRI was defined as most recent MRI while on therapy. Two pediatric radiologists independently determined MRI lesion volume by tracing lesion contours on all slices (normalized to patient body mass index) and signal by placing an ROI on lesions' dominant portion (normalized to CSF signal), on baseline and follow-up T2-weighted sequences. Inter-reader agreement was determined, and values averaged for further analysis. Volume and signal changes were compared with patient, lesion, and therapy characteristics.
Mean (±SD) interval between sirolimus initiation and follow-up MRI was 22.1±13.8 months. Mean lesion volume index on baseline and follow-up MRI was 728 mL/m2 ± 970 mL/m2 and 345 mL/m2±501 mL/m2, respectively (p<.001). Ninety-two percent demonstrated a decrease in volume index >10% (mean volume change -46.4%±28.2%). Volume change was inversely correlated with age (r=-0.466, p=.02). Mean volume change was -64.7%±25.4% in children under 2 years old versus -32.0%±21.6% in remaining children (p=.008). Mean volume change was -58.1%±24.0% for craniocervical lesions versus -35.5%±28.2% for body and extremity lesions (p=.03). Mean lesion signal ratio on baseline and follow-up MRI was 0.81±0.29, and 0.59±0.26, respectively (p<.001). Mean signal ratio change was -23.8%±22.7%. Volume and signal changes were moderately correlated (r=0.469; p=.02). Volume and signal changes were not associated with sex, lesion subtype, sirolimus serum concentration, or interval between sirolimus initiation and follow-up MRI (p>.05). Inter-reader agreement for volume index change was excellent [intraclass correlation coefficient (ICC)=0.983] and for signal ratio change was moderate-good (ICC=0.764).
Sirolimus treatment for extensive LM in children is associated with significant reductions in volume and signal on T2-weighted MRI. The volume decrease is greater in younger children and craniocervical lesions.
The results may facilitate development of standardized MRI-based criteria for assessing pharmacotherapy response of vascular malformations.</description><issn>0361-803X</issn><issn>1546-3141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNo9kEtPAjEUhRujEUR3rk2XLhzsa9phSQgqBmKCGN1NOn2EmnnZzhj595aAru5ZfOfk5gPgGqMxIZjdT5_XYxIzoyI7AUOcMp5QzPApGCLKcZIh-jEAFyF8IoRENhHnYEApQ-mEsSFQq_UC2sbDtQltUwcDpyGYECpTd7CxcP7TmTq4bwOXu6rdys4puJJlbFQxxwJ0NZxtXam9qeHGG9kZDd9dt4Wvzjelq_pwCc6sLIO5Ot4ReHuYb2ZPyfLlcTGbLhNFJrhLNJd0ogtDkZWEWIUyjopUxV8zLrKUKq44iX-LrNAI4ZTI1AokkbaIZEJqOgK3h93WN1-9CV1euaBMWcraNH3ICRMcEyFSHtG7A6p8E4I3Nm-9q6Tf5Rjle6151JqTmPdaI35zXO6Lyuh_-M8j_QUktnK9</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Durand, Rachelle</creator><creator>Reid, Janet R</creator><creator>Belasco, Jean B</creator><creator>Shellikeri, Sphoorti</creator><creator>Calle-Toro, Juan S</creator><creator>Cahill, Anne Marie</creator><creator>Srinivasan, Abhay</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210901</creationdate><title>MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus</title><author>Durand, Rachelle ; Reid, Janet R ; Belasco, Jean B ; Shellikeri, Sphoorti ; Calle-Toro, Juan S ; Cahill, Anne Marie ; Srinivasan, Abhay</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c291t-d6a39dbe30fa22fc0860b5c334867853c6c6240578bd00152a5f70a0df0287ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Durand, Rachelle</creatorcontrib><creatorcontrib>Reid, Janet R</creatorcontrib><creatorcontrib>Belasco, Jean B</creatorcontrib><creatorcontrib>Shellikeri, Sphoorti</creatorcontrib><creatorcontrib>Calle-Toro, Juan S</creatorcontrib><creatorcontrib>Cahill, Anne Marie</creatorcontrib><creatorcontrib>Srinivasan, Abhay</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of roentgenology (1976)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Durand, Rachelle</au><au>Reid, Janet R</au><au>Belasco, Jean B</au><au>Shellikeri, Sphoorti</au><au>Calle-Toro, Juan S</au><au>Cahill, Anne Marie</au><au>Srinivasan, Abhay</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus</atitle><jtitle>American journal of roentgenology (1976)</jtitle><addtitle>AJR Am J Roentgenol</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>217</volume><issue>3</issue><spage>741</spage><epage>752</epage><pages>741-752</pages><issn>0361-803X</issn><eissn>1546-3141</eissn><abstract>Extensive lymphatic malformations (LM) may cause substantial morbidity. The mTOR (mammalian target of rapamycin) inhibitor sirolimus shows promise for treating vascular anomalies, though response assessment is not standardized.
To retrospectively characterize changes on MRI in extensive LM in children treated with sirolimus.
Twenty-five children treated with sirolimus for extensive LM were included. Baseline MRI was defined as MRI closest to therapy initiation; follow-up MRI was defined as most recent MRI while on therapy. Two pediatric radiologists independently determined MRI lesion volume by tracing lesion contours on all slices (normalized to patient body mass index) and signal by placing an ROI on lesions' dominant portion (normalized to CSF signal), on baseline and follow-up T2-weighted sequences. Inter-reader agreement was determined, and values averaged for further analysis. Volume and signal changes were compared with patient, lesion, and therapy characteristics.
Mean (±SD) interval between sirolimus initiation and follow-up MRI was 22.1±13.8 months. Mean lesion volume index on baseline and follow-up MRI was 728 mL/m2 ± 970 mL/m2 and 345 mL/m2±501 mL/m2, respectively (p<.001). Ninety-two percent demonstrated a decrease in volume index >10% (mean volume change -46.4%±28.2%). Volume change was inversely correlated with age (r=-0.466, p=.02). Mean volume change was -64.7%±25.4% in children under 2 years old versus -32.0%±21.6% in remaining children (p=.008). Mean volume change was -58.1%±24.0% for craniocervical lesions versus -35.5%±28.2% for body and extremity lesions (p=.03). Mean lesion signal ratio on baseline and follow-up MRI was 0.81±0.29, and 0.59±0.26, respectively (p<.001). Mean signal ratio change was -23.8%±22.7%. Volume and signal changes were moderately correlated (r=0.469; p=.02). Volume and signal changes were not associated with sex, lesion subtype, sirolimus serum concentration, or interval between sirolimus initiation and follow-up MRI (p>.05). Inter-reader agreement for volume index change was excellent [intraclass correlation coefficient (ICC)=0.983] and for signal ratio change was moderate-good (ICC=0.764).
Sirolimus treatment for extensive LM in children is associated with significant reductions in volume and signal on T2-weighted MRI. The volume decrease is greater in younger children and craniocervical lesions.
The results may facilitate development of standardized MRI-based criteria for assessing pharmacotherapy response of vascular malformations.</abstract><cop>United States</cop><pmid>33405944</pmid><doi>10.2214/AJR.20.24378</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0361-803X |
ispartof | American journal of roentgenology (1976), 2021-09, Vol.217 (3), p.741-752 |
issn | 0361-803X 1546-3141 |
language | eng |
recordid | cdi_proquest_miscellaneous_2476127756 |
source | American Roentgen Ray Society; Alma/SFX Local Collection |
title | MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T08%3A58%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MRI%20for%20Response%20Assessment%20of%20Extensive%20Lymphatic%20Malformations%20in%20Children%20Treated%20With%20Sirolimus&rft.jtitle=American%20journal%20of%20roentgenology%20(1976)&rft.au=Durand,%20Rachelle&rft.date=2021-09-01&rft.volume=217&rft.issue=3&rft.spage=741&rft.epage=752&rft.pages=741-752&rft.issn=0361-803X&rft.eissn=1546-3141&rft_id=info:doi/10.2214/AJR.20.24378&rft_dat=%3Cproquest_cross%3E2476127756%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476127756&rft_id=info:pmid/33405944&rfr_iscdi=true |